Renalytix Plc (NASDAQ:RNLX) Q3 2022 Earnings Conference Call June 30, 2022 8:30 AM ET

Company Participants

James McCullough - Chief Executive Officer

Tom McLain - President

Jim Sterling - Chief Financial Officer

Peter DeNardo - Capcomm Partners

Conference Call Participants

Dan Arias - Stifel

Randy Baron - Pinnacle

Mark Massaro - BTIG

Yi Chen - HC Wainwright

Jens Lindqvist - Investec

Operator

Good morning, and welcome to the Renalytix Conference Call to review Third Quarter Fiscal Year 2022 Financial Results. At this time, all participants are in a listen-only mode. We will be facilitating a question-and-answer session towards the end of the call. As a reminder, this call is being recorded for replay purposes.

I would now like to turn the call over to Peter DeNardo of CapComm Partners for a few introductory comments.

Peter DeNardo

Thank you, Tanya. Thank you all for participating in today’s call. Joining me today from Renalytix are James McCullough, Chief Executive Officer, Tom McLain, President, and Jim Sterling, Chief Financial Officer.

Before we begin, I’d like to remind you that management may make statements during this call that include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements made during this call that relate to expectations or predictions of future events, results or performance are forward-looking statements. Examples of these statements include, without limitation, the potential benefits including economic savings of KidneyIntelX, the potential for KidneyIntelX to receive regulatory approval from the FDA, the commercial prospects for KidneyIntelX if approved, including whether KidneyIntelX will be successfully adopted by a physician and distributed and marketed, our expectations regarding reimbursement decisions and the ability of KidneyIntelX to curtail cost of chronic and end stage kidney disease, optimize care delivery, and improve patient outcomes, trends in our market and potential benefits of government policy change, the impact of COVID-19 and other world events on our business, our expectations for hiring, product development, strategic partnerships and collaborations, reimbursement decisions, clinical studies and regulatory submissions, our business strategies and future growth including plans, expectations and opportunities for financing our operations, and revenue projections and guidance.

These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements. Accordingly, you should not place undue reliance on these statements. For a description of the risks and uncertainties associated with our business, please refer to the Risk Factors section of our annual report on Form 20-F that was filed on October 21 with the Securities and Exchange Commission. All forward-looking statements made on this call are based on management’s current estimates and various assumptions. Renalytix disclaims any intention or obligation except as required by law to update or revise any financial projections or forward-looking statements whether because of new information, future events or otherwise.